Comparison of patients with Parkinson’s disease with and without pain
| Patients with pain (n = 47) | Patients without pain (n = 70) | Odds ratio (95% confidence interval) | p Value | |
|---|---|---|---|---|
| UPDRS, Unified Parkinson’s Disease Rating Scale. | ||||
| Values are mean (SD) unless otherwise stated. | ||||
| *Patients with pain (n = 13) and without pain (n = 4) had both motor fluctuations and dyskinesia. | ||||
| Sex (men/women) | 19/28 | 31/39 | 0.85 (0.4 to 1.8) | 0.7 |
| Age (years) | 69.7 (8.7) | 69.2 (7.6) | 1.1 (0.96 to 1.06) | 0.7 |
| Disease duration (years) | 8.2 (6.6) | 5.3 (3.8) | 1.1 (1.03 to 1.2) | 0.008 |
| Akinetic rigid dominant v tremor dominant phenotype | 17/30 | 29/41 | 0.80 (0.4 to 1.7) | 0.57 |
| UPDRS III during the on state | 19.5 (13.5) | 15.9 (10.8) | 1.02 (0.99 to 1.05) | 0.13 |
| UPDRS III tremor score | 1.5 (2.6) | 1.1 (1.5) | 1.1 (0.89 to 1.34) | 0.37 |
| UPDRS III rigidity score | 3.3 (3.3) | 2.4 (2.4) | 1.05 (0.93 to 1.2) | 0.43 |
| UPDRS III bradykinesia score | 7.8 (5.6) | 6.9 (5) | 1.04 (0.96 to 1.1) | 0.33 |
| Motor complications | 28 | 17 | 6.5 (2.8 to 14.8) | <0.0001 |
| Motor fluctuations* | 19 | 10 | 6.3 (2.4 to 15.9) | <0.0001 |
| Dyskinesia* | 22 | 11 | 7.7 (2.3 to 17.5) | <0.0001 |
| Dopamine agonists | 15 | 25 | 0.9 (0.4 to 2.2) | 0.9 |
| Levodopa treatment | 5.9 (6.8) | 3.6 (4.4) | 1.1 (1.001 to 1.16) | 0.045 |
| Levodopa dosage (mg) | 657 (320) | 617 (357) | 1.001 (1.0004 to 1.02) | 0.042 |
| Other diseases | 14 | 18 | 1.4 (0.66 to 2.93) | 0.4 |
| Depression | 14 | 19 | 1.1 (0.5 to 2.5) | 0.8 |